Literature DB >> 35349618

Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.

Benjamin Gallo Marin1, Rocío Oliva1, Benjamin Kahn1, Theo Borgovan2, Blake Elizabeth Brooks1, Cathy M Massoud1.   

Abstract

Adverse cutaneous reactions associated with the immune checkpoint inhibitor (ICI) pembrolizumab are well documented, yet life-threatening reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are infrequent.1,2 We present a case of pembrolizumab-induced TEN in a patient with metastatic esophageal adenocarcinoma who was successfully treated with cyclosporine and systemic corticosteroids.

Entities:  

Keywords:  Stevens-Johnson syndrome; cyclosporine; pembrolizumab; toxic epidermal necrolysis

Mesh：

Substances：

Year:  2022        PMID： 35349618      PMCID： PMC9053295     

Source DB:  PubMed          Journal:  R I Med J (2013)        ISSN： 0363-7913


  8 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

2.  Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  L Valeyrie-Allanore; P Wolkenstein; L Brochard; N Ortonne; B Maître; J Revuz; M Bagot; J C Roujeau
Journal:  Br J Dermatol       Date:  2010-10       Impact factor: 9.302

3.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

4.  Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses.

Authors:  Florence Poizeau; Olivier Gaudin; Laurence Le Cleach; Tu-Anh Duong; Camille Hua; Claire Hotz; Saskia Ingen-Housz-Oro; Emilie Sbidian; Ouidad Zehou; Audrey Colin; Nicolas de Prost; Bénédicte Lebrun-Vignes; Olivier Chosidow; Pierre Wolkenstein; Laurence Fardet
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

5.  Toxic epidermal necrolysis associated with pembrolizumab.

Authors:  Zhuo Ran Cai; Julie Lecours; Jean-Philippe Adam; Isabelle Marcil; Normand Blais; Mario Dallaire; Annie Belisle; Alexandre Mathieu
Journal:  J Oncol Pharm Pract       Date:  2019-12-06       Impact factor: 1.809

Review 6.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

Review 7.  Immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-23       Impact factor: 11.527

8.  Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.

Authors:  Connie Qiu; Alina Shevchenko; Sylvia Hsu
Journal:  JAAD Case Rep       Date:  2020-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.